Considering the implication of cAMP signaling in cancer biology, the potential to selectively target PKA, EPAC or PDEs, and the possibility of either elevating or reducing cAMP levels in the TME, targeting cAMP signaling pathways holds promise in cancer therapy. The gene discussed is RAPGEF4; the disease is cancer.